Edition:
United States

ARMO Biosciences Inc (ARMO.OQ)

ARMO.OQ on NASDAQ Stock Exchange Global Select Market

49.98USD
21 Jun 2018
Change (% chg)

-- (--)
Prev Close
$49.98
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
105,289
52-wk High
$57.00
52-wk Low
$25.14

Summary

Name Age Since Current Position

Peter Vlasselaer

President, Chief Executive Officer, Founder, Director

Martin Oft

Founder and Vice President - Pre-Clinical and Clinical Development

Russell Kawahata

Vice President - Technical Operations

Scott Ogg

Vice President - Corporate Development and Operations

Gail Brown

Chief Medical Officer

Biographies

Name Description

Peter Vlasselaer

Dr. Peter Van Vlasselaer, Ph.D., is Founder, President, Chief Executive Officer and Director at ARMO BioSciences, Inc. Van Vlasselaer, PhD has over 20 years of experience in the biotech industry and is currently CEO of ARMO BioSciences. Previously, he was CEO of iPierian, ARRESTO and AVIDIA. In addition to founding ARMO, Dr. Van Vlasselaer was a co-founder of Arresto, TrueNorth and ACIR BioSciences and he was a member of the start-up teams of InterMune (ITMN) and Dendreon (DNDN). He currently serves on the boards of ARMO, TrueNorth, and Blade Therapeutics. Dr. Van Vlasselaer has a degree in Zoology and a PhD in Immunology from the Catholic University of Leuven, Belgium. He has authored several peer reviewed scientific publications and book chapters and he is an inventor on multiple patents.

Martin Oft

Dr. Martin Oft, M.D., is the Founder and Vice President - Pre-Clinical and Clinical Development at ARMO BioSciences, Inc. Oft, MD has over 19 years of experience in Biotechnology and Pharmaceutical Research and Development. Most recently he co-founded ARMO to develop immune therapies for the treatment of cancer and other diseases. Prior to ARMO, Martin held positions at DNAX Research Inc. of Schering Plough in Palo Alto, now Merck Research Labs. There, he led multiple development teams to progress immune therapies for the treatment of cancer and led the efforts for the discovery and development of PEGylated IL-10. Previously, Martin served at Onyx Pharmaceuticals, the UCSF Cancer Center, and Boehringer Ingelheim. Martin holds an MD degree and medical license from the University of Erlangen, Germany. He performed his postdoctoral research at the Institute of Molecular Pathology in Vienna, Austria. Martin published numerous scientific articles and reviews on cancer progression and the immune response to cancer and he is an inventor on a number of cancer therapy patents.

Russell Kawahata

Mr. Russell T. Kawahata, Ph.D., is Vice President - Technical Operations of the Company. Kawahata, PhD, has over 25 years of experience in bio-pharmaceutical development and manufacturing. Prior to joining ARMO, Russ was Vice President of Pharmaceutical Science at NeurogesX, where he directed development and manufacturing of Qutenza. Prior to that, he was Vice President of Technical Operations at InterMune where he directed development of a portfolio of clinical and commercial products including Esbriet (pirfenidone). Previously, he held positions of increasing responsibility at Xoma Corp. (XOMA), Systemix and Connetics Corp. (CNCT) where he directed the development of Luxiq (betamethasone valerate), Olux (clobetasol proprionate), and Rogaine (minoxidil) foams. Russ received a Ph.D. in Pharmacology and Toxicology at the University of California, Davis and a B.S. in Biochemistry from the University of California, Berkeley.

Scott Ogg

Dr. Scott Ogg, Ph.D., is Vice President - Corporate Development and Operations at ARMO BioSciences, Inc. Ogg, PhD joined ARMO as its Vice President of Corporate Development and Operations in May 2013. Prior to joining ARMO, Scott was Director, Project and Portfolio Management at Gilead (GILD) where he managed oncology and hepatitis programs. Scott was on the start-up team of ARRESTO BioSciences where he played an instrumental role in the acquisition of the company by Gilead and the completion of the Series B and C financings as Senior Director of Project and Alliance Management. Previously, he held positions of increasing responsibility at Exelixis (EXEL) and Nektar Therapeutics (NKTR) where he managed the early development of MOVANTIK™ (naloxegol). Scott completed post-doctoral studies at Harvard University Medical School/Massachusetts General Hospital and received a Ph.D. in Cellular & Molecular Physiology from Tufts University Sackler School of Graduate Biomedical Sciences and a B.A. in Biology from Albion College. He is author and inventor on several publications and patents.

Gail Brown

Ms. Gail L Brown, M.D., is Chief Medical Officer of the Company. Brown, MD joined ARMO as its Chief Medical Officer and has over 21 years of clinical research and development experience in designing and conducting phase 1 through phase 3 international clinical trials. Most recently, Dr. Brown was Senior Medical Director at AbbVie, Inc. where she worked on the clinical development of Venclexta™ (venetoclax) in hematologic malignancies. Previously, she served as a Senior Technical Analyst for RRD International, LLC and was Chief Medical Officer at Telik, Inc. Earlier in her career, Dr. Brown consulted for a number of oncology start-up companies and participated in their scientific and clinical advisory boards. Dr. Brown began her career at Harvard Medical School, where she served on the faculty of the Department of Medicine, Division of Hematology and Oncology at Brigham and Women’s Hospital, New England Deaconess Hospital and the Dana Farber Cancer Institute. She holds a M.D. degree from the University of Rochester School of Medicine and a M.B.A. degree from St. Mary’s College of California Graduate School of Economics and Business Administration.